Evidence map›Paper›PMID 40807170›Full record

ReviewJournal of clinical medicine2025

SGLT2 Inhibitors and GLP-1 Receptor Agonists in PAD: A State-of-the-Art Review.

Alfredo Caturano, Damiano D'Ardes, Paola Giustina Simeone, Gianfranco Lessiani, Nicoletta Di Gregorio, Lorenzo Andreetto, Davide Grassi, Carla Serra, Francesca Santilli, Maria Teresa Guagnano and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alfredo CaturanoDepartment of Human Sciences and Promotion of the Quality of Life, San Raffaele Roma Open University, 00166 Rome, Italy.ORCID 0000-0001-7761-7533
Damiano D'ArdesInstitute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.ORCID 0000-0001-5573-4536
Paola Giustina SimeoneInstitute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Gianfranco LessianiAngiology Unit, Internal Medicine Department, Città S. Angelo Hospital, Città S. Angelo, 65013 Pescara, Italy.
Nicoletta Di GregorioDepartment of Life, Health & Environmental Sciences and Internal Medicine, ASL Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy.
Lorenzo AndreettoInternal Medicine, IRCCS Azienda Ospedaliero-Universitaria Policlinico di Sant'Orsola, 40138 Bologna, Italy.
Davide GrassiInternal Medicine Unit, Val Vibrata Hospital-Sant'Omero (TE), Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.ORCID 0000-0003-1005-4689
Carla SerraDiagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-5555-0745
Francesca SantilliInstitute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Maria Teresa GuagnanoInstitute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.ORCID 0000-0001-7225-0891
Fabio PiscagliaDiagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-8264-1845
Claudio FerriDepartment of Life, Health & Environmental Sciences and Internal Medicine, ASL Avezzano-Sulmona-L'Aquila, San Salvatore Hospital, University of L'Aquila, 67100 L'Aquila, Italy.
Francesco CipolloneInstitute of "Clinica Medica", Department of Medicine and Aging Science, "G. d'Annunzio" University of Chieti-Pescara, 66100 Chieti, Italy.
Andrea BoccatondaDiagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40138 Bologna, Italy.ORCID 0000-0001-9303-7790

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium-glucose co-transporter-2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP-1 RAs) are now established as cornerstone therapies for patients with type 2 diabetes mellitus (T2DM), given their cardiovascular and renal protective properties. However, their use in patients with peripheral artery disease (PAD) remains controversial due to concerns raised in early trials about potential increases in lower limb complications, particularly amputations. This narrative review examines current evidence on the association between SGLT2is and GLP-1 RAs in PAD-related outcomes, including limb events, amputation risk, and cardiovascular and renal endpoints. Drawing from randomized controlled trials, real-world cohort studies, and systematic reviews, we provide an integrated perspective on the safety and utility of SGLT2is and GLP-1 RAs in individuals with PAD, highlight patient selection considerations, and identify areas for future investigation.

Indexed as

amputation riskcardiovascular outcomesGLP-1 receptor agonists (GLP-1 RAs)peripheral artery disease (PAD)sodium–glucose co-transporter-2 inhibitors (SGLT2is)type 2 diabetes mellitus (T2DM)

Identifiers

PMID40807170
PMCPMC12347938

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.